相关实验视频
Updated: May 24, 2025

05:57
Fat Preference: A Novel Model of Eating Behavior in Rats
Published on: June 27, 2014
13.1K
在儿童和青少年肥胖症中GLP-1受体激活剂
Margaret A Stefater-Richards1,2, Grace Jhe3,4,5, Yanjia Jason Zhang2,6,7
1Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts.
Pediatrics
|March 3, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 为肥胖青少年提供有效的体重控制. 临床医生必须考虑心理健康,营养和健康公平,以获得最佳的GLP-1RA治疗结果.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 在美国,儿童肥胖是一个重要的公共卫生问题,导致许多相关疾病.
- 有效的干预措施需要社会变革和医疗保健创新.
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是最近获得批准用于青少年肥胖症治疗的进展.
研究的目的:
- 审查儿科临床医师对GLP-1RAs在青少年肥胖护理中的有效使用的考虑.
- 概述肥胖药物治疗的历史和发展,包括GLP-1RAs.
- 突出全面肥胖管理的关键方面,包括心理健康,营养和健康公平.
主要方法:
- 对肥胖药理学史和GLP-1RAs的发展进行了回顾.
- 对青少年GLP-1RA使用当前指示的检查.
- 讨论不良反应,心理健康整合,营养考虑和健康公平问题.
主要成果:
- GLP-1RAs在体重管理和改善青少年肥胖相关疾病方面表现出有效性.
- 综合护理必须解决心理健康问题,特别是饮食行为障碍.
- 在GLP-1RA治疗期间,营养状况需要仔细监测.
- 必须解决肥胖风险和治疗机会方面的健康不平等问题,以防止恶化.
结论:
- 在全面的儿科肥胖治疗计划中,GLP-1RAs是一个有价值的工具.
- 整合心理健康支持和营养指导对于成功的药物治疗至关重要.
- 确保公平获得GLP-1RAs至关重要,以避免扩大现有的健康差距.
相关概念视频
Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290
Oral Hypoglycemic Agents: Glinides
129
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
129
Dipeptidyl Peptidase 4 Inhibitors
161
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
161
Regulation of Food Intake
174
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
174
Oral Hypoglycemic Agents: Biguanides and Glitazones
151
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
151
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
142
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
142

